European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
IRVINE, Calif., April 03, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq:SCYX). Investors who purchased shares (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm before the May 8, 2017 lead plaintiff motion deadline.
If you purchased shares of SCYNEXIS during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company’s lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug’s approval prospects and/or commercial viability; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation. When this information was released to the public, shares of SCYNEXIS fell in value, thus harming investors.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
